key: cord-0952469-thzpr1c8 authors: Stip, Emmanuel; Arnone, Danilo; Abdel Aziz, Karim; Javaid, Syed Fahad title: Diversity of mechanism of action of psychotropic drugs in their anti-COVID-19 properties date: 2021-07-19 journal: Mol Psychiatry DOI: 10.1038/s41380-021-01222-x sha: cd81b1a1d2f970d87802d023b518605781f8096e doc_id: 952469 cord_uid: thzpr1c8 nan We read the study by Hoertel et al. [1] with great interest. The authors used a Cox's regression model to evaluate the impact of individuals treated with antidepressants on the outcome following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Of the 7230 patients hospitalized following SARS-CoV-2 infection, 4.8% were treated with antidepressants within the first 48 h of admission. The analysis suggests a 27-57% risk reduction (HR, 0.56; 95% CI, 0.43-0.73, p < 0.001) of intubation or COVID-19 related death in antidepressant-treated subjects. Although the study's retrospective nature does not allow for establishing a causal link that will require a randomized controlled trial, this is an important observational study, which illustrates the possibility that antidepressants might have properties that protect against the action of SARS-CoV-2 virus. There is growing evidence for substantial neurological and psychiatric morbidity following COVID-19 infection, with the greatest risk in patients who had severe COVID-19 [2] . It is of interest that psychotropic compounds commonly used to treat mental disorders exercise a putative preventive effect against the most catastrophic outcomes related to SARS-CoV-2 infection. In complementarity with Hoertel's explanation, we carried out a literature search of PubMed, Google Scholar, and Scopus by using the name of each drug commonly used in mental health or the class of psychotropic drugs as keywords combined with 'antiviral' or 'SARS' or 'COVID-19'. The aim was to identify psychotropic compounds, the level of supporting preclinical or clinical evidence for anti SARS-CoV-2 action, and the putative mechanisms of action. Table 1 reports the emerging evidence for different psychotropics for their anti-SARS CoV-2 action. While the current evidence supports a potential anti SARS-CoV-2 role for several antidepressants including the antipsychotic chlorpromazine, the mood stabilizer lithium, and the anti-dementia drug memantine, the level and strength of evidence remain diverse. The evidence for mood stabilizers, chlorpromazine, and memantine is more speculative at this moment than that for certain antidepressants with substantial clinical, observational, and preclinical data. The literature reports an in vitro action of antidepressants against the activity of acid sphingomyelinase [3, 4] . There is also recent observational evidence to support the potential usefulness of functional inhibitors of acid sphingomyelinase, including antidepressants and antipsychotics, among patients hospitalized for severe COVID-19 [5] . In addition, a possible mechanism of action of psychotropic drugs is related to virus cell entry via clathrin-mediated endocytosis. Another potential action of psychotropic drugs is modifying the balance between pro and antiinflammatory cytokines, which could protect against the most deleterious consequences of an indiscriminate immunological response [6] . One of the advantages of psychotropic drugs is the efficient crossing of the blood-brain barrier and the affinity for synaptic receptors, most of which trigger functions that could interact with the immune system at different levels [6] . Tolerance and safety are vital parameters for drug repurposing to treat or prevent infections with SARS COV-2. Psychotropic medications are widely used in clinical practice with well-known safety and tolerability parameters. Antidepressants, compared to antipsychotics or mood stabilizers, have a favorable safety profile [4] and are better tolerated in older individuals. In conclusion, the realization that psychotropic compounds have potentially significant antiviral properties in the context of SARS-CoV-2 can improve our understanding of these molecules [7] , and also offers a new opportunity for repurposing their role in our pharmacological armamentarium if antiviral characteristics are better characterized in controlled studies. It is premature to launch a meta-analysis or a systematic review because of the number and -Antagonism of α7 nicotinic acetylcholine receptors (α7nAChR) and N-methyl-D-aspartate (NMDA) receptors may decrease angiotensin-converting enzyme 2 (ACE2) receptor expression and reduce oxidative stress and inflammation, hence potentially reducing severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) virulence (Hasanagic & Serdarevic, 2020). -Potent protective effect against lesions induced by 6 hydroxydopamine (6-OHDA) in dopaminergic pheochromocytoma (PC12) cells related to reversing nerve growth factor IB (NGFIB) upregulation. NGFIB activates the nuclear factor-κB (NF-κB) signaling pathway, potentiates the induction of proinflammatory gene expression, and enhances mouse resistance to lipopolysaccharide (LPS)-induced sepsis by inhibiting NF-κB activity, suppressing aberrant cytokine production (Jiménez-Jiménez et al., 2020). -Pharmacological inhibition of ionotropic NMDA glutamate receptors suppresses neurological symptoms of disease and reduces the expression of pro-inflammatory cytokines in the rat brain (Jiménez-Jiménez et al., 2020). Correspondence heterogeneity of clinical studies completed or underway. However, the diversity of the antiviral mechanisms of psychotropic drugs deserves to be studied in a translational way. Emmanuel Stip 1,2 , Danilo Arnone 1,3 , Karim Abdel Aziz 1 and Syed Fahad Javaid 1 ✉ Autophagy Process as a Novel Therapeutic Strategy in COVID-19 Could the antipsychotic chlorpromazine be a potential treatment for SARS-CoV-2? Repurposing prolactin as a promising immunomodulator for the treatment of COVID-19: Are common Antiemetics the wonder drug to fight coronavirus? Med Hypotheses Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials A comprehensive review on potential therapeutics interventions for COVID-19 The Large Action of Chlorpromazine: Translational and Transdisciplinary Considerations in the Face of COVID19 Chlorpromazine as a Potential Antipsychotic Choice in COVID-19 Treatment Plausible role of combination of Chlorpromazine hydrochloride and Teicoplanin against COVID-19 Psychiatry and COVID-19: The Role of Chlorpromazine Psychosis Treatment During COVID-19 Pandemic and the Potential Role of Phenothiazines: A Call for Research Studies Novel treatment targets for COVID-19: Contribution from molecular psychiatry Psychoactive compounds as multifactorial protection factors against COVID-19 e-pub ahead of print Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells Pharmacological Inhibition of Acid Sphingomyelinase Prevents Uptake of SARS-CoV-2 by Epithelial Cells Association between FIASMAs and reduced risk of intubation or death in individuals hospitalized for severe COVID-19: an observational multicenter study Effects of psychotropic drugs on inflammation: consequence or mediator of therapeutic effects in psychiatric treatment? Towards a pharmacochemical hypothesis of the prophylaxis of SARS-CoV-2 by psychoactive substances Anti-Inflammatory Effects of Amantadine and Memantine: Possible Therapeutics for the Treatment of Covid-19? Adamantanes for the Prevention of COVID19: A Review of Case Reports SARS-CoV-2 E protein is a potential ion channel that can be inhibited by Gliclazide and Memantine ES designed and directed the project, developed the theory, and finalized the manuscript. All other authors contributed by reviewing the literature in their respective areas, writing and improving different portions of the manuscript, and approved the submitted version. DA has received travel grants from Jansen-Cilag and Servier and sponsorship from Lundbeck. The other authors report no conflict of interest. Correspondence and requests for materials should be addressed to S.F.J.Reprints and permission information is available at http://www.nature.com/reprintsPublisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.